SMMT Latest Headlines

Citi Keeps Their Buy Rating on Summit Therapeutics (SMMT)

at www.tipranks.com (Wed, 3-Dec 7:47 PM)

SMMT Spotlights Ivonescimab at Four Major Investor Conferences—What’s Next for This Promising Oncology Platform?

Market Chameleon (Tue, 4-Nov 8:44 AM)

Summit Therapeutics Secures $500 Million Funding Led by Insiders and Institutions—Fueling Ivonescimab Clinical Advancements

Market Chameleon (Wed, 22-Oct 8:22 AM)

SMMT Earnings Surprise: Why Has Summit Therapeutics Fallen Despite Clinical Wins? Historical Trends Reveal the Stock's Pattern

Market Chameleon (Mon, 20-Oct 9:57 AM)

Ivonescimab’s Progress in NSCLC Drives Summit’s Clinical Pipeline Expansion and Higher R&D Investment

Market Chameleon (Mon, 20-Oct 7:32 AM)

Summit Therapeutics Sets October 20, 2025 for HARMONi-6 ESMO Data Update and Q3 Earnings Call

Market Chameleon (Wed, 15-Oct 9:16 AM)